72 Jane Street m 
New York N Y 10014 'R! 
(212)675-7173 X 
Coalition for 
Responsible Genetic Research 
ADVISORY COUNCII 
John S. Bird M D. 
Dr. Irwin Bross 
Helen Caldicott M li • 
Dr. Liebe Cavalieri* 
John C. Cobb M D • 
Dr. Douglas DeNiku 
Dr. Key Dismukes* 
W. Jack Frumin M ll 
Solomon Carb M L> • 
Steven Havas M O ' 
Dr. Ruth Hubbard* 
Dr. Marvin Kalkstent' 
J.R Kent M.D. 
Dr. Jonathan King* 
Dr. Sheldon Krimsky* 
Elliot Linzer* 
Pamela Lippe* 
Joyce Milton 
Lewis Mumford* 
Dr. Stuart Newman* 
Christine Oliver Mil* 
David Ozonoff M D • 
Dr. Barbara Rosenheig* 
David Straton M D ' 
Dr. George Wald*, 
Nobel Laureate 
Susanna Waterman* 
Dr. Joseph Weizenhmim* 
Dr. Susan Wright* 
'Executive Comm/ft cp 
MEMBERSHIP. 
PARTIAL LISTING 
Walter Askinas MO 
David R. Brower 
Rev. Roger Burgess 
Sir MacFarlane Burnet 
Nobel Laureate 
Stuart Chase 
Citizens Rights Commute* 
Glen C. Cobb M.D 
Dr. C. David Elm 
William D. Furst M II 
Reverend David A tmimess 
Mariano L. Calaineva M o 
W.B. Gamble Jr. M 1 1 
F.M. Golomb M D 
Dr. Mario A. Conzaler 
Harold J. Harris M 1 1 
Dr. Kenneth L. Jack.,,,, 
Father Walter T. Kcl| P |„, r 
Hadley Kirkman M 1 1 
Dr. Laura Kratz 
Henry D. Lauson M |i 
Dr. Herbert Manning 
Edwin F. Matthews | ( 
Edward Miller M D 
Robert Murphy M 11 
Maurice L. Origene* K\ |) 
Dr. Aurelio Peccei 
Henry Pinkerton M |l 
Eliot Porter 
Dr. Jerome Prager 
Dr. Steven Price 
Sister Mary E Reic licit 
Abby Rockefeller 
Lewis M. Schiffer M |i 
Solomon Garb MO 
Membership Secretary 
Francine R. Simring 
Executive Director 
COMMENTS ON PROPOSED REVISED GUIDELINES FOR 
RECOMBINANT DNA RESEARCH 
FEDERAL REGISTER, JULY 28, 1978 
PART IV 
imOVUCTION 
This section of comments on the proposed revised Guide- 
lines concerning protection of the health of the potentially 
exposed worker is the third of a three-part report submitted 
by the Coalition for Responsible Genetic Research. 
Part I - Structures and Procedures 
Part II - Technical Analysis and Comments 
Part III- Protection of Employees 
The following comments indicate areas of inadequacy, re- 
commend improvements and changes, and also touch on the mechanism 
for policy change: 
I. I ndu&t/ujaZ Regulation 
The Guidelines provide only for voluntary compliance by 
industry with its standards and procedures, "...provision is 
now made for the private sector to register voluntarily its re- 
combinant DNA activities with the NIH." (p. 33045) Because of 
the voluntary nature of the directive, industry will not be sub- 
ject to sanctions for non-compliance. This is especially of con- 
cern because volume-oriented production sharply increases the 
probabilities of biologic mishap and worker exposure. 
[A-402] 
